News

Industries

Companies

Jobs

Events

People

Video

Audio

Galleries

My Biz

Submit content

My Account

Advertise with us

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants.
(Image: Wikimedia Commons)
(Image: Wikimedia Commons)

Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation.

Once cirrhosis is established, the annual risk of hepatic decompensation defined as the development of ascites, hepatic encephalopathy or variceal bleeding, is 42% [1]. These statistics highlight the importance of recurrent HCV after LT, which in turn has stimulated the controversy surrounding retransplantation of recurrent HCV, particularly in the first post-operative year when retransplantation for severe recurrence is not recommended due to poor outcomes [2]. Read on

About Professor Sandeep Mukherjee

Professor Sandeep Mukherjee, MBBCh, MPH, FRCPC is Associate Professor in Internal Medicine, University of Nebraska Medical Centre, Omaha, Nebraska.
Let's do Biz